Pay in 4 interest-free payments of $5.62 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
Clinical Trial Outcomes with Monotherapy The REDEFINE 1 trial demonstrated that cagrilintide monotherapy at the 4.5 mg maintenance dose produced mean body weight reductions of approximately 10.8% from baseline after 32 weeks of treatment [4]
prescribed off-label for weight loss Estimated retail price: $950$1,200/month Zepbound (tirzepatide) FDA approved for weight loss Estimated retail price: $1,080$1,200/month Mounjaro (tirzepatide) FDA approved for type 2 diabetes
One key pharmacologic distinction matters for hepatic impairment specifically
Inflammation reduction manifests in many ways, from decreased joint pain to improved energy levels
Thus providing you with a comfortable and secure treatment environment
The study did, however, also highlighted several negative side effects, including constipation (118 occurrences), diarrhea (100 events), and abdominal pain (41 events per 1,000) (48)
